A Phase I, Randomized, Cross-over, Single-Center, Single Dose Fasted Study of EG-101 IV Injection (EG-ZNMP-01) in Healthy Volunteers to Serve as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia
Latest Information Update: 19 Jan 2026
At a glance
- Drugs EG 101 (Primary)
- Indications Preeclampsia
- Focus Pharmacokinetics
- Sponsors Evergreen Therapeutics
Most Recent Events
- 19 Jan 2026 New trial record